CureVac disappoints in COVID vaccine trial
Listen now
Description
After a slew of wildly successful vaccine trials, this week marked a more underwhelming result. The third mRNA vaccine to complete phase three trials, developed by CureVac, is just 47% effective at staving off disease according to preliminary data. This is a stark contrast with previous mRNA vaccines from Moderna and Pfizer BioNtec which returned around twice that efficacy in their trials. In this episode of Coronapod, we ask why the CureVac vaccine has faltered, and what this might mean for the future of the pandemic and mRNA vaccine development. News: CureVac COVID vaccine let-down spotlights mRNA design challenges News Feature: How COVID unlocked the power of RNA vaccines Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday.   See acast.com/privacy for privacy and opt-out information.
More Episodes
Early in 2021 the United Kingdom, along with several other countries, allowed mass gatherings as part of a series of controlled studies aimed at better understanding the role events could play in the pandemic. The goal was to inform policy - however early results have provided limited data on...
Published 07/24/21
Funding for gun violence research in the US returns after a 20-year federal hiatus, and the glass sponges that can manipulate ocean currents.   See acast.com/privacy for privacy and opt-out information.
Published 07/21/21
The UK government has announced that virtually all COVID restrictions will be removed in England on Monday 18th July. This will do away with social distancing requirements, allow businesses to re-open to full capacity and remove legal mask mandates. This decision comes, however, amidst soaring...
Published 07/16/21